MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations

Transl Lung Cancer Res. 2024 Apr 29;13(4):940-946. doi: 10.21037/tlcr-24-98. Epub 2024 Apr 25.

Authors

Jan Trøst Jørgensen¹, Edyta M Urbanska², Jens Mollerup³

Affiliations

¹ Medical Sciences, Dx-Rx Institute, Fredensborg, Denmark.
² Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
³ Pathology Division, Agilent Technologies Denmark ApS, Glostrup, Denmark.

No abstract available

Keywords: MET exon 14-skipping mutations (METex14); Non-small-cell lung cancer (NSCLC); capmatinib; companion diagnostics; tepotinib.

Publication types

Editorial
Comment